Strs Ohio Purchases New Shares in Omnicell, Inc. $OMCL

Key Points

• Strs Ohio has acquired a new stake in Omnicell, Inc., purchasing 161,186 shares valued at approximately $5.64 million, representing 0.34% of the company's stock.
• Recent analyst reports show varying target prices for Omnicell, with Wells Fargo raising its target from $37.00 to $40.00 and Bank of America adjusting its target from $30.00 to $34.00.
• Omnicell reported $0.45 earnings per share for its latest quarter, exceeding estimates, with revenue of $290.56 million reflecting a 5.0% year-over-year increase.

Strs Ohio purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 161,186 shares of the company's stock, valued at approximately $5,635,000. Strs Ohio owned 0.34% of Omnicell at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of OMCL. Deutsche Bank AG raised its stake in Omnicell by 23.0% during the fourth quarter. Deutsche Bank AG now owns 52,493 shares of the company's stock valued at $2,337,000 after purchasing an additional 9,822 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Omnicell by 44.5% in the fourth quarter. ProShare Advisors LLC now owns 13,766 shares of the company's stock valued at $613,000 after acquiring an additional 4,238 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Omnicell in the fourth quarter valued at $30,637,000. Two Sigma Investments LP raised its stake in shares of Omnicell by 44.2% in the fourth quarter. Two Sigma Investments LP now owns 141,738 shares of the company's stock valued at $6,310,000 after acquiring an additional 43,471 shares during the period. Finally, Squarepoint Ops LLC raised its stake in shares of Omnicell by 286.4% in the fourth quarter. Squarepoint Ops LLC now owns 149,717 shares of the company's stock valued at $6,665,000 after acquiring an additional 110,966 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Performance

OMCL traded down $0.46 during trading on Friday, reaching $31.34. 1,383,338 shares of the company's stock were exchanged, compared to its average volume of 488,885. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock has a market capitalization of $1.44 billion, a P/E ratio of 62.68, a price-to-earnings-growth ratio of 6.94 and a beta of 0.82. The company's fifty day simple moving average is $30.95 and its 200-day simple moving average is $30.89.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business's revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on OMCL shares. Piper Sandler reduced their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Bank of America upped their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 3,880 shares of Omnicell stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the transaction, the executive vice president directly owned 110,653 shares of the company's stock, valued at $3,679,212.25. The trade was a 3.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is currently owned by company insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.